SecBot SecBot
S-3ASR ·Filed May 7, 2026

BBIO

BridgeBio Pharma, Inc.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001140361-26-019654
Notable filing: S-3ASR
Actionable Insight ◆ Mixed

The simultaneous $500M ATM and $500M buyback authorization creates a complex signal, management sees stock as undervalued (buyback) but wants capital flexibility (ATM). Monitor actual ATM usage vs. buyback execution in coming quarters; heavy ATM usage would signal capital needs despite strong cash position. The Q1 revenue beat and pipeline catalysts (three NDAs in 2026) provide fundamental support, but the ATM overhang may cap near-term upside. Watch for insider selling patterns and any accelerated ATM draws.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$67.39
T+0 close · May 8, 2026 · via day close
Latest settled
+21.78%
T+60 · $82.07
Vs SPY
+16.94%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $67.39entry
  2. T+1 · 6mo ago −4.02%α −4.25% · $64.68
  3. T+5 · 6mo ago +3.37%α +1.90% · $69.66
  4. T+20 · 5mo ago +0.33%α +0.30% · $67.61
  5. T+60 · 3mo ago +21.78%α +16.94% · $82.07

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio Pharma filed an automatic shelf registration (S-3ASR) to register an unlimited amount of securities, including a $500 million at-the-market (ATM) common stock offering via Goldman Sachs and Leerink Partners. The filing comes one day after reporting strong Q1 2026 results with $194.5M in total revenue, $180.6M in U.S. Attruby net product revenue, and $940.2M in cash, alongside a newly authorized $500M share repurchase program. The ATM offering provides capital flexibility but creates potential dilution of up to ~3.8% of shares outstanding at current prices.

Key Facts

  • S-3ASR filed May 7, 2026 registering unlimited securities, with a $500M ATM common stock offering via Goldman Sachs and Leerink Partners
  • Q1 2026 total revenues of $194.5M, including $180.6M U.S. Attruby net product revenue, $9.5M royalty revenue, and $4.4M license/services revenue
  • Cash, cash equivalents, and marketable securities of $940.2M as of March 31, 2026
  • Board authorized a $500M share repurchase program concurrently with the ATM offering
  • 195,707,702 shares outstanding as of March 31, 2026; up to 7,343,222 shares could be sold at $68.09/share to raise full $500M (3.8% dilution)
  • Sales agents receive up to 3.0% commission on gross proceeds from ATM sales
  • Proceeds intended for general corporate purposes including R&D, commercialization, working capital, debt repayment, and potential acquisitions
  • Three late-stage pipeline candidates (BBP-418, encaleret, infigratinib) with NDAs submitted or planned for 2026

Financial Impact

Up to $500M in potential equity issuance at-the-market, representing ~3.8% dilution at current price; partially offset by $500M buyback authorization creating potential net neutral capital return

dilutionshares outstandingcash position

Risk Factors

  • ATM sales could pressure stock price through continuous selling into the market
  • Dilution of up to 3.8% if full $500M is drawn at current prices
  • Buyback may not offset dilution if ATM is used aggressively
  • Biotech sector volatility and regulatory risks for pipeline candidates
  • Convertible debt overhang (~37.8M shares reserved for conversion across four note series)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
97% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
S-3ASR Filing (Primary)0001140361-26-019654
Document: ny20072667x1_ex4-4.htm0001140361-26-019654

Track record

38 reports on BBIO

Performance horizon

10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $77.36 −1.04% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $77.36 +3.22% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $77.36 +9.23% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $77.36 +13.56% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $77.36 +22.21% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (11h 46m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026